Cancer Family
Leukemia
CI-CAN-00000215Explore in graph →
HematologicTop-level1,769 active trials42 approved drugs708 evidence items
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000215Explore in graph →
Clinical trials
8,437 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (1,348)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT02953301 | Resminostat for Maintenance Treatment of Patients With Advanced Stage Mycosis Fungoides (MF) or Sézary Syndrome (SS)(RESMAIN) | completed | Phase 2 | 201 | 4SC AGINDUSTRY | 12 | Aug 30, 2024 | clinicaltrials |
| NCT02096055 | Guadecitabine With or Without Idarubicin or Cladribine in Treating Older Patients With Previously Untreated Acute Myeloid Leukemia | completed | Phase 2 | 44 | M.D. Anderson Cancer CenterOTHER | 1 | Aug 27, 2024 |
| clinicaltrials |
| NCT04847050 | A Trial of the Safety and Immunogenicity of the COVID-19 Vaccine (mRNA-1273) in Participants With Hematologic Malignancies and Various Regimens of Immunosuppression, and in Participants With Solid Tumors on PD1/PDL1 Inhibitor Therapy | completed | Phase 2 | 19 | National Cancer Institute (NCI)NIH | 1 | Aug 27, 2024 | clinicaltrials |
| NCT02157181 | Treatment of Hairy Cell Leukaemia Variant and Relapsing Hairy Cell Leukaemia With Cladribine Plus Rituximab | completed | Phase 2 | 89 | Jurgen BarthOTHER | 1 | Aug 22, 2024 | clinicaltrials |
| NCT04605666 | CD19-CAR-T2 Cells for CD19 Positive B Cell Malignancies | completed | Phase 2 | 77 | Nanfang Hospital, Southern Medical UniversityOTHER | 1 | Aug 20, 2024 | clinicaltrials |
| NCT01199575 | Phase II Trial of Revlimid® and Rituximab for Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) | completed | Phase 2 | 30 | University of California, San DiegoOTHER | 1 | Aug 15, 2024 | clinicaltrials |
| NCT04204057 | Efficacy and Safety of Tenalisib (RP6530) in Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL) | completed | Phase 2 | 21 | Rhizen Pharmaceuticals SAINDUSTRY | 3 | Aug 13, 2024 | clinicaltrials |
| NCT03275636 | Haploidentical Donor vs mMUD in Hematological Malignancies(HAMLET) | completed | Phase 2 / Phase 3 | 98 | DKMS gemeinnützige GmbHOTHER | 1 | Aug 7, 2024 | clinicaltrials |
| NCT02001818 | Pegylated Interferon Alfa-2b and Nilotinib for Augmentation of Complete Molecular Response in Chronic Myeloid Leukaemia(PInNACLe) | completed | Phase 2 | 60 | Australasian Leukaemia and Lymphoma GroupOTHER | 1 | Aug 6, 2024 | clinicaltrials |
| NCT00042003 | Phase II Trial of Decitabine in Patients With Chronic Myelogenous Leukemia Blast Phase Who Are Refractory to Imatinib Mesylate (Gleevec) | completed | Phase 2 | 40 | Astex Pharmaceuticals, Inc.INDUSTRY | 2 | Aug 2, 2024 | clinicaltrials |
| NCT02113982 | Tagraxofusp in Patients With Blastic Plasmacytoid Dendritic Cell Neoplasm or Acute Myeloid Leukemia | completed | Phase 1 / Phase 2 | 138 | Stemline Therapeutics, Inc.INDUSTRY | 1 | Aug 1, 2024 | clinicaltrials |
| NCT03902665 | Up-front Hematopoietic Stem Cell Transplantation in Acute Myeloid Leukemia Patients Aged 65-75 | completed | Phase 2 | 19 | Fondazione Policlinico Universitario Agostino Gemelli IRCCSOTHER | 1 | Jul 23, 2024 | clinicaltrials |
| NCT02807272 | Tipifarnib in Subjects With Chronic Myelomonocytic Leukemia, Other MDS/MPN, and Acute Myeloid Leukemia(CMML/AML) | completed | Phase 2 | 44 | Kura Oncology, Inc.INDUSTRY | 1 | Jul 17, 2024 | clinicaltrials |
| NCT02626715 | Reduced-Intensity Conditioning (RIC) and Myeloablative Conditioning (MAC) for HSCT in AML/MDS | completed | Phase 2 | 21 | Randy WindreichOTHER | 1 | Jul 16, 2024 | clinicaltrials |
| NCT02400281 | Study of Crenolanib Combined With Chemotherapy in FLT3-mutated Acute Myeloid Leukemia Patients | completed | Phase 1 / Phase 2 | 28 | Arog Pharmaceuticals, Inc.INDUSTRY | 1 | Jul 3, 2024 | clinicaltrials |
| NCT04969601 | Anti-Covid-19 Vaccine in Children With Acute Leukemia and Their Siblings(PACIFIC) | completed | Phase 1 / Phase 2 | 76 | Assistance Publique - Hôpitaux de ParisOTHER | 1 | Jun 26, 2024 | clinicaltrials |
| NCT04835519 | Phase I/II Study of Enhanced CD33 CAR T Cells in Subjects With Relapsed or Refractory Acute Myeloid Leukemia | completed | Phase 1 / Phase 2 | 5 | Beijing Boren HospitalOTHER | 1 | Jun 21, 2024 | clinicaltrials |
| NCT02199184 | Dose Adjusted EPOCH Regimen in Combination With Ofatumumab or Rituximab in Treating Patients With Newly Diagnosed or Relapsed or Refractory Burkitt Lymphoma or Relapsed or Refractory Acute Lymphoblastic Leukemia | completed | Phase 2 | 14 | M.D. Anderson Cancer CenterOTHER | 1 | Jun 11, 2024 | clinicaltrials |
| NCT04629443 | Phase I/II Trial of S64315 Plus Azacitidine in Acute Myeloid Leukaemia | completed | Phase 1 / Phase 2 | 17 | Institut de Recherches Internationales ServierOTHER | 4 | Jun 6, 2024 | clinicaltrials |
| NCT00590187 | Efficacy Study of Oral Sapacitabine to Treat Acute Myeloid Leukemia in Elderly Patients | completed | Phase 2 | 105 | Cyclacel Pharmaceuticals, Inc.INDUSTRY | 1 | Jun 4, 2024 | clinicaltrials |
| NCT03493646 | Evaluating in Vivo AZA Incorporation in Mononuclear Cells Following Vidaza or CC486 | completed | Phase 2 | 40 | Kirby InstituteOTHER_GOV | 1 | May 28, 2024 | clinicaltrials |
| NCT01995578 | Maintenance Low Dose 5'-Azacitidine Post T Cell Depleted Allogeneic Stem Cell Transplantation for Patients With Myelodysplastic Syndrome and Acute Myelogenous Leukemia With High Risk for Post-Transplant Relapse | completed | Phase 2 | 32 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | May 22, 2024 | clinicaltrials |
| NCT03678493 | A Study of FMT in Patients With AML Allo HSCT in Recipients | completed | Phase 2 | 100 | Masonic Cancer Center, University of MinnesotaOTHER | 1 | May 16, 2024 | clinicaltrials |
| NCT03047993 | Glutaminase Inhibitor CB-839 and Azacitidine in Treating Patients With Advanced Myelodysplastic Syndrome | completed | Phase 1 / Phase 2 | 28 | M.D. Anderson Cancer CenterOTHER | 1 | May 14, 2024 | clinicaltrials |
| NCT04942730 | Benadamustine, Fludarabine and Busulfan Conditioning in Recipients of Haploidentical Stem Cell Transplantation (FluBuBe)(FluBuBe) | completed | Phase 2 | 50 | St. Petersburg State Pavlov Medical UniversityOTHER | 1 | May 7, 2024 | clinicaltrials |
| NCT01597219 | Trial of Haploidentical Stem Cell Transplantation for Haematological Cancers(UK-Haplo) | completed | Phase 2 | 77 | University College, LondonOTHER | 1 | May 3, 2024 | clinicaltrials |
| NCT05433532 | Study of Azacitidine，Venetoclax，and Flumatinib in Newly Diagnosed Ph-positive Acute Leukemia and CML-AP/BP Patients | completed | Phase 2 | 20 | The First Affiliated Hospital of Soochow UniversityOTHER | 1 | Apr 25, 2024 | clinicaltrials |
| NCT01751997 | Family-mismatched/Haploidentical Donors Versus Matched Unrelated Donors | completed | Phase 2 / Phase 3 | 116 | Byung-Sik ChoOTHER | 1 | Apr 19, 2024 | clinicaltrials |
| NCT04202003 | A Study to Evaluate the Safety and Tolerability, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of TJ011133 as Monotherapy and in Combination With Azacitidine (AZA) in Patients With Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS) | completed | Phase 1 / Phase 2 | 105 | TJ Biopharma Co., Ltd.INDUSTRY | 1 | Apr 15, 2024 | clinicaltrials |
| NCT02100423 | Curcumin and Cholecalciferol in Treating Patients With Previously Untreated Stage 0-II Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma | completed | Phase 2 | 35 | Paolo Caimi, MDOTHER | 1 | Apr 12, 2024 | clinicaltrials |
| NCT02340884 | A Pilot RCT of the PRISM Intervention for AYAs With Cancer | completed | Phase 2 | 92 | Seattle Children's HospitalOTHER | 1 | Apr 9, 2024 | clinicaltrials |
| NCT02930109 | A Study of PTX-200 (Triciribine) Plus Cytarabine in Refractory or Relapsed Acute Leukemia | completed | Phase 1 / Phase 2 | 33 | Prescient Therapeutics, Ltd.INDUSTRY | 1 | Apr 5, 2024 | clinicaltrials |
| NCT04554485 | Blinatumomab Followed by High-dose Chemotherapy for Ph-negative Acute Lymphoblastic Leukemia (ALL)(Blina-CELL) | completed | Phase 2 | 27 | Institute of Hematology and Blood Transfusion, Czech RepublicOTHER | 1 | Apr 4, 2024 | clinicaltrials |
| NCT03056339 | Umbilical & Cord Blood (CB) Derived CAR-Engineered NK Cells for B Lymphoid Malignancies | completed | Phase 1 / Phase 2 | 49 | M.D. Anderson Cancer CenterOTHER | 1 | Mar 25, 2024 | clinicaltrials |
| NCT02135874 | Clofarabine, Idarubicin, Cytarabine, Vincristine Sulfate, and Dexamethasone in Treating Patients With Newly Diagnosed or Relapsed Mixed Phenotype Acute Leukemia | completed | Phase 2 | 16 | M.D. Anderson Cancer CenterOTHER | 1 | Mar 22, 2024 | clinicaltrials |
| NCT02420912 | Nivolumab and Ibrutinib in Treating Patients With Relapsed, Refractory, or High-Risk Untreated Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, or Richter Transformation | completed | Phase 2 | 37 | M.D. Anderson Cancer CenterOTHER | 1 | Mar 20, 2024 | clinicaltrials |
| NCT01386619 | NK DLI in Patients After Human Leukocyte Antigen (HLA)-Haploidentical Hematopoietic Stem Cell Transplantation (HSCT) | completed | Phase 1 / Phase 2 | 15 | University Hospital, Basel, SwitzerlandOTHER | 2 | Mar 19, 2024 | clinicaltrials |
| NCT02632721 | A Trial to Find and Investigate a Safe Dose of BI 836858 in Combination With Decitabine for Patients With Acute Myeloid Leukemia (AML) | completed | Phase 1 / Phase 2 | 49 | Boehringer IngelheimINDUSTRY | 4 | Mar 19, 2024 | clinicaltrials |
| NCT03267030 | Asparaginase Encapsulated in Erythrocytes for Patients With ALL and Hypersensitivity to PEG-asparaginase | completed | Phase 2 | 55 | Birgitte Klug AlbertsenOTHER | 6 | Mar 15, 2024 | clinicaltrials |
| NCT01858740 | Selective Depletion of CD45RA+ T Cells From Allogeneic Peripheral Blood Stem Cell Grafts in Preventing GVHD in Children | completed | Phase 2 | 20 | Fred Hutchinson Cancer CenterOTHER | 1 | Mar 12, 2024 | clinicaltrials |
| NCT00235560 | Rapamycin in Combination With Low-dose Aracytin in Elderly Acute Myeloid Leukemia Patients(LAM-RAPA) | completed | Phase 2 | 50 | University Hospital, ToulouseOTHER | 1 | Feb 29, 2024 | clinicaltrials |
| NCT02441803 | Allogeneic Hematopoietic Stem Cell Transplantation (AlloSCT) Initial Salvage Therapy for Induction Failure Acute Myeloid Leukemia (AML) | completed | Phase 2 | 11 | M.D. Anderson Cancer CenterOTHER | 1 | Feb 22, 2024 | clinicaltrials |
| NCT03335267 | Investigator Initiated Trial of CPX-351 for Untreated Acute Myeloid Leukemia | completed | Phase 2 | 30 | Weill Medical College of Cornell UniversityOTHER | 1 | Feb 22, 2024 | clinicaltrials |
| NCT00577278 | A Phase II Study of Allo-HCT for B-Cell NHL Using Zevalin, Fludarabine and Melphalan | completed | Phase 2 | 41 | City of Hope Medical CenterOTHER | 1 | Feb 16, 2024 | clinicaltrials |
| NCT01812252 | Chemotherapy in Treating Patients With Myelodysplastic Syndrome Before Donor Stem Cell Transplant(ICT-HCT) | completed | Phase 2 | 50 | Fred Hutchinson Cancer CenterOTHER | 1 | Feb 15, 2024 | clinicaltrials |
| NCT02435849 | Study of Efficacy and Safety of CTL019 in Pediatric ALL Patients(ELIANA) | completed | Phase 2 | 80 | Novartis PharmaceuticalsINDUSTRY | 11 | Feb 13, 2024 | clinicaltrials |
| NCT02473146 | Gemtuzumab Ozogamicin+Cytarabine vs Idarubicin+Cytarabine in Elderly Patients With AML.Mylofrance 4(ALFA1401) | completed | Phase 2 / Phase 3 | 225 | Versailles HospitalOTHER | 1 | Feb 2, 2024 | clinicaltrials |
| NCT01522469 | Phase II Study of Crenolanib in Subjects With Relapsed/Refractory AML With FLT3 Activating Mutations | completed | Phase 2 | 14 | Arog Pharmaceuticals, Inc.INDUSTRY | 1 | Jan 30, 2024 | clinicaltrials |
| NCT01904136 | Natural Killer Cells Before and After Donor Stem Cell Transplant in Treating Patients With Acute Myeloid Leukemia, Myelodysplastic Syndrome, or Chronic Myelogenous Leukemia | completed | Phase 1 / Phase 2 | 54 | M.D. Anderson Cancer CenterOTHER | 1 | Jan 24, 2024 | clinicaltrials |
| NCT02663622 | Phase II Trial of Efprezimod Alfa (CD24Fc, MK-7110) for the Prevention of Acute Graft-Versus-Host Disease (GVHD) Following Myeloablative Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) (MK-7110-002) | completed | Phase 2 | 44 | Oncoimmune, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)INDUSTRY | 1 | Jan 23, 2024 | clinicaltrials |
Data updated 22 days agoSource updated Aug 30, 2024source: clinicaltrials